- Anterior Scleritis
- Diffuse Scleritis
- Nodular Scleritis
- Necrotizing Scleritis
- Posterior Scleritis
- Others
Scleritis Market size was value at USD x million in 2023 and is poised to grow at a CAGR of 5.8% during the forecast period 2024-2030. Scleritis is a medical condition where inflammation occurs in episcleral and scleral tissues with injection in both superficial and deep episcleral vessels. It is reported to cause damage to the cornea, adjacent episclera, and the uvea and thus can be vision-threatening. Scleritis is often associated with an underlying systemic disease in up to 50% of patients and is linked to autoimmune diseases when the body's immune system attacks and destroys healthy body tissue. For example, rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases.
According to a report, out of every 100,000 people, 71 are diagnosed with rheumatoid arthritis each year and around 1.5 million Americans have rheumatoid arthritis. Women are about two to three times more likely to get rheumatoid arthritis than men. The growing geriatric population and increasing per capita income in economic countries, healthcare expenditure, new diagnostic tools, and new therapies invention will drive the overall scleritis market growth. Along with that, the rising prevalence of arthritis, technological advancements in treatment and diagnosis, and the rising incidence of eye diseases will also boost scleritis market growth.
According to a report, of 217 061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100 000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Hence, the global scleritis market is expected to maintain its growth during the forecasted years. However, lack of awareness and the absence of targeted treatment and therapies are expected to hinder the scleritis market growth during the forecast period.
In Oct 2020, U.S. Food and Drug Administration approved Opdivo (nivolumab) and Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
Study Period
2024-2030Base Year
2023CAGR
5.8%Largest Market
Asia PacificFastest Growing Market
North America
The increasing prevalence of scleritis and arthritis is the key driver of the global scleritis market. It is much more observable in aged patients. The growing geriatric population is fueling the market growth in a positive manner. According to WHO, the number and proportion of people aged 60 years and older in the population are increasing. In 2019, the number of people aged 60 years and older was 1 billion. This number will increase to 1.4 billion by 2030 and 2.1 billion by 2050. Hence, the growing geriatric population will drive the global scleritis market in the forecasted years.
By Product Type
By Diagnostic Test
By End-User
The scleritis market is projected to expand at a CAGR of 5.8% during the forecast period
Amgen, Amneal Pharmaceuticals, Baxter International, Boehringer Ingelheim, Mylan Pharmaceuticals, Novartis Pharmaceuticals
North America is the fastest-growing region for the scleritis market
1. Executive Summary |
2. Global Scleritis Market Introduction |
2.1. Global Scleritis Market Taxonomy |
2.2. Global Scleritis Market Definitions |
2.2.1. By Type |
2.2.2. By Diagnostic Test |
2.2.3. By Treatment |
2.2.4. By End User |
2.2.5. By Region |
3. Global Scleritis Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Scleritis Market Dynamic Factors - Impact Analysis |
3.6. Global Scleritis Market Competition Landscape |
3.7. Epidemiology |
4. Global Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Scleritis Market, By Type, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.1. Anterior Scleritis |
5.1.1. Diffuse Scleritis |
5.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Nodular Scleritis |
5.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Necrotizing Scleritis |
5.1.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.2. Posterior Scleritis |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Scleritis Market, By Diagnostic Test, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
6.1. Ultrasonography |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Complete Blood Count |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Biopsy |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Scleritis Market, By Treatment, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
7.1. Medication |
7.1.1. Corticosteroid |
7.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
7.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.1.3. Market Opportunity Analysis |
7.1.2. Nonsteroidal Anti-Inflammatory Drugs |
7.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
7.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.2.3. Market Opportunity Analysis |
7.1.3. Immunosuppressive Drugs |
7.1.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
7.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3.3. Market Opportunity Analysis |
7.2. Surgery |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Scleritis Market, By End User, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
8.1. Hospitals and Clinics |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Diagnostic Centers |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Academic and Research Institutes |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Scleritis Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Region, 2024 -2030 |
10. North America Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
10.1. Type Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Anterior Scleritis |
10.1.1.1. Diffuse Scleritis |
10.1.1.2. Nodular Scleritis |
10.1.1.3. Necrotizing Scleritis |
10.1.2. Posterior Scleritis |
10.1.3. Others |
10.2. Diagnostic Test Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Ultrasonography |
10.2.2. Complete Blood Count |
10.2.3. Biopsy |
10.2.4. Others |
10.3. Treatment Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Medication |
10.3.1.1. Corticosteroid |
10.3.1.2. Nonsteroidal Anti-Inflammatory Drugs |
10.3.1.3. Immunosuppressive Drugs |
10.3.2. Surgery |
10.4. End User Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospitals and Clinics |
10.4.2. Diagnostic Centers |
10.4.3. Academic and Reaserach Institutes |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2024 -2030 |
10.7. North America Scleritis Market Dynamics Trends |
11. Europe Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
11.1. Type Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Anterior Scleritis |
11.1.1.1. Diffuse Scleritis |
11.1.1.2. Nodular Scleritis |
11.1.1.3. Necrotizing Scleritis |
11.1.2. Posterior Scleritis |
11.1.3. Others |
11.2. Diagnostic Test Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Ultrasonography |
11.2.2. Complete Blood Count |
11.2.3. Biopsy |
11.2.4. Others |
11.3. Treatment Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Medication |
11.3.1.1. Corticosteroid |
11.3.1.2. Nonsteroidal Anti-Inflammatory Drugs |
11.3.1.3. Immunosuppressive Drugs |
11.3.2. Surgery |
11.4. End User Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospitals and Clinics |
11.4.2. Diagnostic Centers |
11.4.3. Academic and Reaserach Institutes |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Rest of Europe |
11.6. Europe Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2024 -2030 |
11.7. Europe Scleritis Market Dynamics Trends |
12. Asia-Pacific Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
12.1. Type Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Anterior Scleritis |
12.1.1.1. Diffuse Scleritis |
12.1.1.2. Nodular Scleritis |
12.1.1.3. Necrotizing Scleritis |
12.1.2. Posterior Scleritis |
12.1.3. Others |
12.2. Diagnostic Test Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Ultrasonography |
12.2.2. Complete Blood Count |
12.2.3. Biopsy |
12.2.4. Others |
12.3. Treatment Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Medication |
12.3.1.1. Corticosteroid |
12.3.1.2. Nonsteroidal Anti-Inflammatory Drugs |
12.3.1.3. Immunosuppressive Drugs |
12.3.2. Surgery |
12.4. End User Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospitals and Clinics |
12.4.2. Diagnostic Centers |
12.4.3. Academic and Reaserach Institutes |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2024 -2030 |
12.7. Asia-Pacific Scleritis Market Dynamics Trends |
13. Latin America Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
13.1. Type Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Anterior Scleritis |
13.1.1.1. Diffuse Scleritis |
13.1.1.2. Nodular Scleritis |
13.1.1.3. Necrotizing Scleritis |
13.1.2. Posterior Scleritis |
13.1.3. Others |
13.2. Diagnostic Test Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Ultrasonography |
13.2.2. Complete Blood Count |
13.2.3. Biopsy |
13.2.4. Others |
13.3. Treatment Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Medication |
13.3.1.1. Corticosteroid |
13.3.1.2. Nonsteroidal Anti-Inflammatory Drugs |
13.3.1.3. Immunosuppressive Drugs |
13.3.2. Surgery |
13.4. End User Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospitals and Clinics |
13.4.2. Diagnostic Centers |
13.4.3. Academic and Reaserach Institutes |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2024 -2030 |
13.7. Latin America Scleritis Market Dynamics Trends |
14. Middle East and Africa Scleritis Market Analysis, 2019 - 2023 and Forecast, 2024 -2030 (Revenue, USD Mn) |
14.1. Type Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Anterior Scleritis |
14.1.1.1. Diffuse Scleritis |
14.1.1.2. Nodular Scleritis |
14.1.1.3. Necrotizing Scleritis |
14.1.2. Posterior Scleritis |
14.1.3. Others |
14.2. Diagnostic Test Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Ultrasonography |
14.2.2. Complete Blood Count |
14.2.3. Biopsy |
14.2.4. Others |
14.3. Treatment Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Medication |
14.3.1.1. Corticosteroid |
14.3.1.2. Nonsteroidal Anti-Inflammatory Drugs |
14.3.1.3. Immunosuppressive Drugs |
14.3.2. Surgery |
14.4. End User Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospitals and Clinics |
14.4.2. Diagnostic Centers |
14.4.3. Academic and Reaserach Institutes |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Scleritis Market - Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2024 -2030 |
14.7. MEA Scleritis Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key Types, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Amgen |
15.2.2. Amneal Pharmaceuticals |
15.2.3. Baxter International |
15.2.4. Boehringer Ingelheim |
15.2.5. Mylan Pharmaceuticals |
15.2.6. Novartis Pharmaceuticals |
15.2.7. Perrigo Company |
15.2.8. Fresenius Kabi |
15.2.9. Jubilant Cadista Pharmaceuticals |
15.2.10. Roxane Laboratories |
15.2.11. Sandoz Inc |
15.2.12. Shanghai Henlius Biotech |
15.2.13. Teva Pharmaceuticals |
16. Research Methodology |
17. Key Assumptions and Acronyms |